

## Ethical Insulin Solutions Consulting Group

<u>Team Member Name</u>	<u>Year</u>	<u>Major</u>
Jacob Boyanski	2025	Business Administration and Management
Morgan Darling	2024	English Literature and Writing
Colby Derocher	2024	Business Administration and Management
Jordan Fisher	2024	Business Administration and Management
Garrett Schnorr	2024	Physics

**Advisor(s):** Dr. Edwin J. Portugal, Caitlyn M. Fields

**Topic:** Ethical Considerations of Insulin Affordability and Availability

**Audience:** Board of Directors of Eli Lilly and Company

### Executive Summary

We, Ethical Insulin Solutions Consulting Group have conducted an in-depth analysis focusing on the ethical considerations of insulin affordability and availability from Eli Lilly and Company. As a prominent figure in the insulin market like Sanofi and Novo Nordisk, Eli Lilly possesses the unique opportunity to lead by example and prioritize ethical practices that benefit both the company and the individuals relying on its products.

Our analysis underscores a significant disparity between the production costs of insulin, and its market prices, which frequently exceed reasonable affordability levels. We find this discrepancy has the potential to strongly influence stakeholder perceptions of Eli Lilly's corporate ethics, as public opinion suggests that access to life-saving medication should not be contingent on financial status. Additionally, we highlight the differences in insulin pricing between the United States and other nations, highlighting the necessity for pricing strategies that harmonize profitability with affordability. While we commend Eli Lilly's efforts in taking steps to enhance accessibility and affordability, such as providing \$35 vouchers to high-need users during the pandemic, we would like to propose additional measures to ensure sustainable and ethical pricing practices moving forward. Our recommendations include the forging of partnerships with other insulin manufacturers to collectively uphold higher ethical standards, establishment of a standardized price for insulin and the formulation of new company policies to regulate intermediaries involvement.

As an external consulting group, analyzing the legal, financial, and ethical dimensions of insulin accessibility and affordability. Our findings support our presented solution. We will commence by providing an overview of the ethical considerations surrounding insulin affordability and availability, highlighting their critical importance. Subsequently, we will present our solution, which involves a comprehensive approach that addresses the ethical considerations, balancing profitability and accessibility of insulin for those who need it. Following this, we will delve into the supporting dimensions, including legal aspects, business dynamics, and ethical considerations, to provide a holistic view of the topic. Finally, we will conclude by summarizing the key points discussed and reiterating the significance of ethical practices in ensuring insulin accessibility and affordability. By embracing these recommendations, Eli Lilly and Company can reaffirm its commitment to ethical practices, bolster its reputation as a leader in the pharmaceutical industry, and most importantly, guarantee access to life-saving medication for patients in need. We are fully prepared to support Eli Lilly and Company on this transformative journey toward a more ethical and sustainable future.